Santa Rosa firm TriVascular names new CEO

  • TriVascular2 officers amid packed equipment for their newest venture, from left:Joseph Humphrey, Robert Whirley and Michael Chobotov, President and CEO. Thanks to a $65 million infusion of venture capital the shut-down TriVascular is back in business as TriVascular2 in Santa Rosa.

    Mark Aronoff

Santa Rosa medical technology maker TriVascular has appointed a new chief executive officer as its co-founder steps into a different role.

Christopher G. Chavez, who led the neuromodulation division at St. Jude Medical for the past five years, will assume the post immediately, TriVascular said.

He succeeds TriVascular co-founder and CEO Michael Chobotov, who will stay with the company as chief technology officer and director.

TriVascular's Ovation Abdominal Stent Graft has been approved for sale in Europe since January 2011 and won regulatory approval last November for limited use in the United States. It is designed to treat abdominal aortic aneurysms, a potentially deadly medical condition that affects about 2 million U.S. patients a year.

Chavez joined St. Jude in 2005 when it acquired Advance Neuromodulation Systems, where he was CEO and president.

© The Press Democrat |  Terms of Service |  Privacy Policy |  Jobs With Us |  RSS |  Advertising |  Sonoma Media Investments |  Place an Ad
Switch to our Mobile View